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Optimal  management  of  synchronous  colorectal  liver  metastases  demands  a well-
organized  inter-disciplinary  strategy  by  surgeon,  oncologist  and  radiologist.  Over  the  past
decade, advances  in  management  strategies  of patient  with  liver-limited  metastases  have
incredibly  improved  the  overall  prognosis.  This  review  discusses  the  advances  made  in the
management  of  patients  with  colorectal  cancer  liver  metastases.
A literature  search  was  performed,  using  the  following  databases:  PubMed,  SCOPUS  sci-
encedirect,  EMBASE,  and  NHS Knowledge  Network.  The  retrieved  articles  were  assessed
for  relevance  for  inclusion  in this  review.  The  review  illustrates  that although  currently
surgery  offers the best chance  of cure  in  patients  with  colorectal  liver  metastases,  the
majority  of  patients  are  not  initially  resectable  due  to  the size,  anatomic  location,  extent  ofeoadjuvant  therapy disease, inadequate  remnant  liver volume,  or comorbidities.  This  necessitates  other  treat-
ment modalities  to control  or downsize  the hepatic  lesions  before  embarking  on  the  surgical
intervention.  Systemic  and  regional  chemotherapy  complements  the  surgical  cure  in  the
majority of  patients.© 2013  The  Saudi  Society  of  Microscopes.  Production  and  hosting  by  Elsevier  Ltd.
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1. Introduction
Colorectal cancer (CRC) accounts for more than 51,000
deaths each year in the United States, making it the sec-
ond  most common cause of cancer-related deaths [1] with
an  estimated 49,380 annual deaths [2]. Globally, the inci-
dence  of CRC varies signiﬁcantly with higher incidence
rates in North America, Australia and northern and western
Europe, whereas developing countries have lower rates,
particularly Africa and Asia. The Kingdom of Saudi Arabia
is  considered to be a country with a low CRC incidence;
however, CRC incidence and related mortalities have been
steadily  increasing in the country over the past twenty
years [3,4]. It now ranks ﬁrst among all cancers in males and
third  among females in Saudi Arabia [5]. Approximately
25% of patients have colorectal liver metastases (CRLM) at
the  time of diagnosis while another 25% will develop CRLM
during  course of the disease, making a 50% incidence of
CRLM  at some point of the disease. Eventually two  thirds
of  patients with liver metastases form colorectal cancer will
die  of their CRLM [6]. A multi-disciplinary management
strategy by a well-coherent team of medical oncologist,
surgeon, and radiologist, is offered to deal with CRLM. Con-
troversy  prevails amongst clinicians about which patients
with  CRLM are most suitable for surgical liver resection
and who are candidates of treatment by the non-surgical
means. This study is an overview of the current manage-
ment modalities for CRLM with a brief description of the
merits  and demerits of each strategy.
2. Surgical management of patients with CRLM
Surgical therapy of CRLM remains the only therapeu-
tic option with potential for cure [7,8]. According to the
current  literature, the overall 5-year survival after hepatic
resection with curative intent ranges from 35% to 58% [9].
Without  treatment, survival for patients with CRC liver
metastases is <1% at 5 years [10].
2.1. Criteria for hepatic resection of colorectal metastases
Traditionally, liver resection for CRLM was indicated
only in patients who had ≤3 unilobar metastases, pre-
senting a minimum of 12 months after resection of the
primary tumor, with at least a 1-cm predicted resection
margin of healthy liver parenchyma around the metasta-
sis,  without nodal or extrahepatic disease. These surgical
criteria certainly limited liver surgery to less than 10%
of  patients with liver-limited disease. However, extensive
training and expertise has reported that patients outside
these  guidelines can have reasonable prognosis after liver . .  . . . . . .  .  . .  . . .  .  . . .  . . . . .  .  . . . .  .  . .  . .  .  . .  . . .  . . .  . . . .  .  . . . . .  . . .  .  .  . . . . .  . . . . 5
resection  [11]. The American Hepato-Pancreatico-Biliary
Association consensus conference on resectability of CRLM
[12]  has redeﬁned that the lesions should be deemed
resectable if (1) the disease can be completely resected; (2)
two  adjacent liver segments can be spared with adequate
inﬂow, outﬂow, and biliary drainage; and (3) the volume of
liver  remaining after resection is adequate. It is generally
accepted that an adequate post resection liver remnant is
20%  of the pre resection liver volume.
2.2. Current surgical strategies
When  hepatic metastases are diagnosed synchronously
with the primary CRC, the sequence of surgical interven-
tion remains controversial. Historically, the management
of synchronous CRLM (sCRLM) has been managed by extir-
pation  of primary CRC, followed by chemotherapy and
then  a liver-focused operation to address the CRLM at
the  last stage. Later on, better understanding of the biol-
ogy  of sCRLM has led the surgeons to re-program the
plan  by considering other operative sequences such as
a  liver-ﬁrst (reverse strategy) staged approach, in which
the  hepatic disease is addressed, followed by extirpation
of the primary CRC at later date [13,14]. First reported
by Mentha and colleagues in 2006, the reverse strategy
approach was  proposed as a possible means to minimize
the delay in treating CRLM in patients with sCRLM [15]. This
approach  may  be particularly beneﬁcial for patients with
rectal  cancer because they often require chemotherapy,
radiotherapy, and a complex pelvic operation. The classic
staged  approach, rectal tumor followed by liver resection,
can  result in a signiﬁcant delay in the treatment of CRLM. A
liver-ﬁrst  strategy may  be more applicable to patients with
sCRLM  and a rectal primary [13].
Mayo et al. conducted a multicenter international
review of 1004 patients with CRC and sCRLM to compare
the  outcomes of simultaneous CRC and liver operation with
either  a “classic” staged approach or a liver-ﬁrst strategy
[9].
In  patients with clearly resectable CRLM, studies have
suggested a simultaneous surgical approach for both the
primary  CRC and CRLM [16]. Mayo et al. conducted a
multicenter international review of 1004 patients with
CRC  and sCRLM to compare the outcomes of simultaneous
CRC and liver operation with either a “classic” staged
approach or a liver-ﬁrst strategy [9]. Ninety-day postop-
erative mortality was  3.0%, with no difference between
simultaneous and staged approaches (p = 0.94). The overall
median  and 5-year survivals were 50.9 months and 44%,
respectively; long-term survival was the same regardless
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hat simultaneous and staged resections for sCRLM can
e  performed with comparable morbidity, mortality, and
ong-term  oncologic outcomes.
Other  published studies have proposed that simulta-
eous resection increases both morbidity and cumulative
uration of hospitalization [17,18]. However, Capussotti
t  al. have shown that simultaneous resections were not
ssociated with increased hepatic complications (perihep-
tic  abscess from translocation of intestinal bacteria or
ecreased hepatocyte regeneration) or colonic complica-
ions (anastomotic leakage) when compared with staged
rocedures [19]. A French multicentric study reported a 7%
perative  mortality for simultaneous resection versus 2%
or  staged resections [20] and in a monocentric US study
he  mortality was 12% for simultaneous resection versus
%  for staged resection [21]. Another review concluded
hat major hepatectomies should be performed as a part
f  simultaneous resections only in young (<70 year-old),
ell-selected patients and not with rectal surgery [22]. Age
s  often considered as a criterion when evaluating candi-
ates  for liver resection; among patients in a French cancer
egistry, age >75 years was the strongest predictor of symp-
omatic  treatment used alone and was an independent
redictor for reduced use of chemotherapy and surgical
reatment [23]. Younger age (<75 years) is also indepen-
ently associated with a higher likelihood of undergoing
urative surgery (liver resection) for both synchronous and
etachronous disease [24].
Rapid growth of metastases after removal of the pri-
ary tumor has been demonstrated in several mouse
odels [25,26]. Loss of primary tumor-induced inhibition
f  angiogenesis in the metastases has been suggested as
he  underlying mechanism. Another research suggested
hat vascular density in human colorectal liver metastases
ncreased after resection of the primary tumor, and that
he  increase in vascular density had a positive effect on the
rowth  of the CRLM in humans [27]. The conclusion was
hat  a primary tumor may  inhibit the growth of its metas-
ases  and that this inhibitory effect on tumor growth was
eversed when the primary tumor was resected. However,
he  relevance of this phenomenon in the clinical setting is
till  unknown. As per the available data, the best surgical
trategy to deal with the sCRLM still remains controver-
ial and further evidence-based research is needed for a
lobally  accepted surgical approach.
. Chemotherapy
.1. Different chemotherapeutic agents and regimes
Oncosurgical strategies have improved long-term out-
omes  in patients with CRLM [28,29]. Five-year overall
urvival reported in recent series reaches 58% [30,31]. How-
ver,  numerous chemotherapeutic cycles before surgery
ave  been related to more postoperative complications
32,33] but this data is still debatable. Some studies did not
escribe  any impact of preoperative chemotherapy on sur-
ical  outcomes after resection of colorectal liver metastases
34–36].
New  agents like irinotecan, an inhibitor of topoiso-
erase I, or oxaliplatine, a non-nephrotoxic platinumd Ultrastructure 1 (2013) 1–7 3
complex added to 5 FU-LV (FOLFIRI and FOLFOX com-
binations) obtained a tumor response in approximately
40–50% of the patients [37]. In a recent publication by the
same  group 12.5% patients were converted by chemother-
apy to a resectable status with a 5-year overall survival
rate of 33% for the resected patients [38]. The administra-
tion of triple combination associating CPT-11, oxaliplatin
and 5FU-LV appears to further increase the efﬁcacy of
systemic chemotherapy. A response rate as high as 70%
was  obtained in 3 different studies which improved the
overall  median survival to 26 months [39–41]. The latest
development is the introduction of two  monoclonal anti-
bodies,  cetuximab (Erbitux), a monoclonal antibody against
the  epithelial growth factor receptor and bevacizumab
(Avastin), a humanized antibody against the vascular
endothelial growth factor. Response rates of 43–81% were
reported with cetuximab in combination with irinotecan or
oxaliplatin  and 5 FU-LV in phase I or II-studies in ﬁrst-line
therapy [42].
3.2.  Adjuvant and neoadjuvant chemotherapy
Adjuvant chemotherapy after surgery may  have an
effect on micrometastatic disease and therefore reduces
the  risk of recurrence [43]. Early evidence of the poten-
tial  advantage of adjuvant therapy was  illustrated from a
pooled  analysis of two  randomized trials of 278 patients.
These trials investigated the administration of six cycles
of  bolus 5-FU after surgery (vs. no adjuvant treatment),
and the pooled analysis showed trends nearing statisti-
cal  signiﬁcance in favor of the 5-FU treatment [44]. Some
patients with primary unresectable CRLM may  become
candidates for curative resection following tumor shrink-
age  with downsizing (or conversion) chemotherapy [45]. A
systematic  analysis of ﬁve prospective trials and one ret-
rospective study found that the resection rate in patients
with liver-limited metastases strongly correlated with the
objective  response rate (ORR) to chemotherapy (r = 0.96;
p  = 0.002) [46]. Combination regimens, such as FOLFOX
and FOLFIRI, offer high response rates in the ﬁrst-line
treatment of mCRC: ORRs of 54–58% have been reported
in  phase III populations with metastases at any tissue
site [31]. Another study demonstrated that neoadjuvant
chemotherapy with cetuximab yields high response rates
for  unresectable CRLM by downsizing tumors for curative
resection [47].
In  the nonrandomized controlled trials, there was sig-
niﬁcant heterogeneity with regard to chemotherapeutic
regimens, number of cycles, and timing of chemotherapy
[48]. Some studies compared resection alone to resection
plus preoperative chemotherapy, and found that there
were  no obvious differences in the resectability rates
[49–51]. Chemotherapy produces a wide range of effects on
the  liver parenchyma including steatosis, steatohepatitis
and sinusoidal obstruction syndrome. Steatosis is charac-
terized by lipid-containing vesicles that alter hepatocyte
function [52]. Steatohepatitis represents more severe liver
damage,  characterized by steatosis with lobular inﬂam-
mation and hepatocyte ballooning, probably derived from
chemotherapy-induced oxidative lipid peroxidation and
cytokine  release.
copy an4 S.Y. Guraya / Journal of Micros
The issue of the recommended duration of chemother-
apy before or after resection of liver metastases remains
unresolved. The 6-cycle course was the ﬁrst one studied,
and  there have been no comparisons with shorter or longer
therapy  plans, leaving this decision at the discretion of the
treating  physicians.
3.2.1.  Hepatic artery infusion (HAI)
HAI is an attractive method of locoregional control for
CRLM,  and provides high drug exposure of the tumor at
ﬁrst  passage, capable of overcoming some drug resistance
mechanisms, such as drug efﬂux [53]. HAI reproducibly
yields higher response rates than intravenous (IV) ther-
apy.  Administering drugs via the hepatic artery results in a
higher  exposure of, and a higher drug clearance by tumor
cells,  compared to normal hepatocytes and, consequently,
yields a more selective killing of cancer cells. Floxuridine
(FUDR), a prodrug of 5-FU with a hepatic extraction rate
>90%  that results in a hepatic/systemic ratio of 100–400
is  more suitable for HAI than 5-FU with a hepatic extrac-
tion rate <50% and a hepatic/systemic ratio around 10 [54].
Similarly,  promising results were reported by using HAI of
doxorubicin analog [55] and oxaliplatin [56]. In the meta-
analysis of all published randomized trials for HAI, the
response rate was 42.9% with HAI, versus 18.4% with the
IV  route. Achieving a response was 2.26-fold more likely
with  HAI than with IV infusion (p < 0.0001) [54].
Placement failures of the intra-arterial catheter or
further complications (catheter obstruction, hepatic
artery thrombosis or dissection, catheter leakage, bleed-
ing/infection of the pump pocket, and extra-hepatic
perfusion, responsible for gastroduodenal ulcus) have
limited the beneﬁts of HAI in the management of CRLM.
Toxicity of HAI-induced therapy, especially chemi-
cal hepatitis, biliary sclerosis, gastroduodenal ulcur,
and gastroduodenitis [57] often leading to treatment
discontinuation and suboptimal treatment duration.
Gastrointestinal complications of HAI were responsible
for a very variable rate of 5–52% in a meta-analysis [58].
Looking into the beneﬁts and complications of HAI, the
role  of HAI in CRLM should, therefore, be revisited, using
modern multidisciplinary therapeutic approaches and
appropriate study designs.
3.2.2.  Portal vein embolization (PVE)
Experimental research has conﬁrmed that hemi-liver
deprived of portal ﬂow will atrophy and that the remnant
liver  with an increased portal ﬂow will increase its vol-
ume  in a few weeks. Since 1982, Makuuchi and colleagues
have used PVE to initiate compensatory hypertrophy of the
future  remnant liver in patients planned for major liver
resection for cancer [59]. In patients with an otherwise
normal liver, existing guidelines recommend preoperative
PVE when the ratio of the remnant liver volume to the
total  estimated liver volume is less than 30% [60]. Patients
subjected to extensive neoadjuvant chemotherapies with
a  high risk of induced parenchymal hepatic lesions should
beneﬁt  from this method when this ratio is less than 40%
[61].  The efﬁcacy of PVE has been quantiﬁed concerning the
size  of the future remnant liver and the clinical impact. A
study  on 30 patients with unresectable CRLM due to a veryd Ultrastructure 1 (2013) 1–7
small  liver remnant at the initial evaluation, showed that
PVE  increased the remnant liver from a mean of 26% to a
mean  of 37%, allowing curative surgery in all cases [62].
A  potential problem with PVE in patients with bilobar
metastases is the growth of the tumors on the ipsilateral
side. A report observed that during liver regeneration after
right  portal embolization, the growth rate of liver metas-
tases  on the left side was more rapid than that of the
liver parenchyma [63]. PVE increases tumor growth and
probably is associated with enhanced recurrence of dis-
ease  [64]. Based on such limitations, PVE is recommended
in a selected group of patients with CRLM with carefully
customized surgical strategy.
4. Other locoregional treatments for CRLM
4.1. Radiofrequency thermal ablation (RFTA)
RFTA is a very popular radiological technique for local
destruction of CRLM and has gained acceptance due to rel-
ative  ease of its use, and its effectiveness for the treatment
[65]. It is indicated for the patients who  are not candidates
for resection due to comorbidities, location of metastatic
lesions, or inadequate liver remnant volume. RFTA may be
performed  during open laparotomy, either alone or with
oncomitant hepatic resection or other procedures; laparo-
scopically via 2–3 incisional ports; or percutaneously. For
the  treatment of CRLM the place of radiofrequency ther-
mal  ablation (RFTA) is still debated: RFTA can be used as:
(1)  as a deﬁnitive treatment per se; (2) as a complement to
progenerative procedures, such as PVE; or (3) in the treat-
ment  of recurrences after surgery. RFTA must be restricted
to  cases in which the size of the dominant lesion is less than
3  cm or when a maximum of three tumors are present [66].
In  a study on percutaneous RFTA for CRLM, local control
was  achieved in 78% of tumors <2.6 cm,  but only in 47% of
tumors  2.6–4.0 cm and 32% of tumors >4.0 cm [67].
The precise anatomic location of the liver metastasis
can pose a limitation of RFTA. If applied close to a large
hepatic vessel, the heat sink effect signiﬁcantly increases
the  risk of incomplete ablation. Also, the danger of thermal
injury is enhanced when nodules are close to main biliary
structures or to extrahepatic organs. In such situations, new
RFTA  techniques or additional procedures, such as hepatic
inﬂow  occlusion or intraductal cooling, have to be con-
sidered [68,69]. Currently, RTFA cannot replace surgery in
patients  with completely resectable disease, its effective-
ness  is considered in the treatment of early small hepatic
recurrences which developed after the surgical resection
[70].
4.2.  Selective internal radiation therapy (SIRT)
SIRT or radioembolization administers yttrium-90
microspheres via catheter into the hepatic artery target-
ing  the CRLM. The philosophy of SIRT is based on the
anatomical fact that blood supply for much of the nor-
mal  liver parenchyma arrives through portal circulation.
The microsphere size precludes access to the venous cir-
culation,  therefore, a high radiation dose (>100 Gy) is
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paring normal liver parenchyma [71]. This challenging
echnique can be considered for highly selected patients
ith unresectable metastases [45]. More randomized con-
rolled  clinical trials are awaited to establish the long-term
urative role of SIRT.
.3.  Cryotherapy
This procedure involves the introduction of liquid nitro-
en  through metallic probes inserted into the tumor. This
esults  in rapid freezing of the tissue to produce tumor
ecrosis. However, cryotherapy has not gained global
opularity due to its high rate of complications, with
perative mortality rates approaching 7%; notably torren-
ial  hemorrhage from the damaged hepatic parenchyma,
isseminated intravascular coagulation, and incomplete
umor ablation [72].
.4.  Stereotactic body radiotherapy (SBRT)
This technique involves the administration of high radi-
tion  dose targeting directly and accurately to the CRLM
n  a limited number of fractions, with sharp dose gra-
ients surrounding the target. Outcomes following SBRT
ere  evaluated in a pooled tri-institutional analysis of
5  patients with CRLM estimated that a dose range of
6–52  Gy delivered in 3 fractions was required to achieve
 1-year local control rate of >90% [73].
. Conclusion
The current management for CRLM is complex, rapidly
volving and carries multiple challenges. Surgical resec-
ions  of the CRLM are the mainstay of treatment provided
he  lesions fulﬁll the resection criteria. Perioperative
hemotherapy may  improve outcome in patients under-
oing  liver resections. Also the patients whose CRLM are
nitially  unresectable may  be beneﬁted from chemother-
py to identify a subgroup who may  beneﬁt later from
esection. Other locoregional therapies have heterogenous
esults and further multicentre prospective clinical trials
ill  testify their long-term survival outcomes.
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